Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia Von Tresckow, Anja Engelke, Christian Maurer, Gabor Kovacs, Marco Herling, Eugen Tausch, Karl Anton Kreuzer, Barbara Eichhorst, Sebastian Böttcher, John F. Seymour, Paolo Ghia, Paula Marlton, Michael KnebaClemens Martin Wendtner, Hartmut Döhner, Stephan Stilgenbauer, Michael Hallek

Research output: Contribution to journalArticle

Abstract

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-näivepatientswithCLL.The primary end pointwas progressionfree survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for theFCRand FCgroup (hazardratio[HR], 0.59; 95%confidence interval [CI], 0.50- 0.69, P<.001).Median overall survival (OS)was not reached for the FCRgroup and was 86.0 months for the FC group (HR, 0.68; 95% CI, 0.54-0.89, P 5 .001). In patients with mutated IGHV(IGHVMUT),FCRimprovedPFSandOScomparedwithFC(PFS:HR, 0.47; 95%CI, 0.33-0.68,P

Original languageEnglish
Pages (from-to)208-215
Number of pages8
JournalBlood
Volume127
Issue number2
DOIs
Publication statusPublished - Jan 14 2016

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., Von Tresckow, J., Engelke, A., Maurer, C., Kovacs, G., Herling, M., Tausch, E., Kreuzer, K. A., Eichhorst, B., Böttcher, S., Seymour, J. F., Ghia, P., Marlton, P., ... Hallek, M. (2016). Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood, 127(2), 208-215. https://doi.org/10.1182/blood-2015-06-651125